Mazou Ngou Temgoua: Why Does Apixaban Cause Less Bleeding than Rivaroxaban?
Mazou Ngou Temgoua, Contract hospital practitioner at Châteauroux-Le Blanc Hospital Center, shared on LinkedIn about a recent article by Lana A. Castellucci et al, adding:
“Why does apixaban cause less bleeding than rivaroxaban?
A recent trial in VTE shows a lower incidence of bleeding with apixaban compared to rivaroxaban.
But the real question lies elsewhere:
Where does this difference come from?
Several avenues:
1. Pharmacokinetics
- Apixaban is given in 2 doses – more stable concentrations
- Rivaroxaban in 1 dose – higher plasma peaks
2. Intensity of factor Xa inhibition
A more ‘smoothed’ inhibition could further preserve physiological hemostasis
3. Induction Diagram (highlighted in this article)
- 7 days for apixaban
- 21 days for rivaroxaban
Are we really comparing two molecules… or two anticoagulation strategies?
Key Message:
- If the difference is related to the schema, it is potentially modifiable.
And this opens up a simple question:
Should we rethink the initial phase of rivaroxaban in VTE?
The answer is not yet known.
But the debate deserves to be asked.
And you, what is your reading?”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on NEJM
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 17:36Paul Whiteley: Neurodevelopmental and Autism Risks in Fetal and Neonatal Alloimmune Thrombocytopenia
-
Jun 24, 2026, 17:22Kavitha Dev: A Low Platelet Count Isn’t Always Critical, But It Should Never Be Ignored
-
Jun 24, 2026, 17:04Recurrent Cervical Internal Carotid Vasospasm Linked to Autosomal Recessive PTGIS Defect – International Journal of Stroke
-
Jun 24, 2026, 16:49Gaurav Kharya: Bridging the Gap in Safe Blood Access for Patients Who Can’t Wait
-
Jun 24, 2026, 16:40William Wallace: Vitamin C and Collagen Work as One Biological System
-
Jun 24, 2026, 16:32Arlindo Nascimento de Lemos Junior: Thrombus Echogenicity as a Predictor of Post-Thrombotic Syndrome Severity After DVT
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc